 |
Investor Relations
|
Vitro Receives Adult Stem Cell Patent from the United States Patent and Trademark Office
Golden, Colorado—June 9, 2009—Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced that it has been awarded United States Patent number 7,527,971 entitled, “Generation and Differentiation of Adult Stem Cells.”
The patent provides protection to a specific cell line derived from human pancreatic tissues that gives rise to structures comparable to the Islets of Langerhans (beta islets). These islets also synthesize and secrete insulin in response to elevated glucose levels, as do beta islets contained within pancreatic tissue. Vitro has also developed a process for the commercial production its cell line-derived islets. Furthermore, the Company previously obtained regulatory approval for an animal protocol to determine reversal of Type I diabetes, a critical step in the demonstration of efficacy. Thus, the recently issued patent affords an exclusive proprietary position to the Company for a new cellular therapy to treat Type I diabetes.
Dr. Jim Musick, Vitro’s President and CEO said, “We are pleased to announce the issuance of our new patent from the USPTO. We intend to develop our patented technology into a viable therapy for Type I diabetes. Our issued United States patents now include production of FSH, a fertility drug, methods and compositions for production of immortalized human cells, and adult stem cells. We also own patent-pending technology for stem cell therapy of cancer. Our patent portfolio complements our recently launched, “Tools for Stem Cell and Drug Development™,” a series of commercially available products for use in stem cell research targeting human mesenchymal stem cells, induced pluripotent stem cells and stem cell-based cancer research. Our business plan includes commercialization and expansion of our recently launched products to support stem cell research and drug development while we also pursue development of stem cell-based therapies for diabetes and cancer, chronic conditions with enormous costs to patients, society and global health care systems.”
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG; http://www.vitrobiopharma.com) is committed to “Harnessing the Power of Cells”. Vitro owns US patents for production of the fertility drug, FSH, immortalization of cells, and adult stem cells. The Company also owns a pending US patent regarding stem cell-based cancer treatments. Vitro recently established a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is commercialization of “Tools for Stem Cell and Drug Development™”. In addition, Vitro’s stem cell technology has shown promise for development of stem cell therapy for diabetes and cancer.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130
E-mail: jim@vitrodiag.com
Source: Vitro Diagnostics, Inc.